EUVIMEDEUVIMED entdecken
BeobachtungsstudieVergleichsstudieOpen Access · CC BY 4.0

Counterfeit ‘Xanax®’ tablets: A comparative study of clinical and seizure data in Victoria, Australia

Rebekka Syrjanen iD, Shaun L Greene iD, Sarah E Hodgson iD, Rachelle Abouchedid iD, Dimitri Gerostamoulos iD, Christie Magee, Melissa Bremner, Jennifer L Schumann iD, Emerging Drugs Network of Australia – Victoria (EDNAV) research group

Addiction · 2025

DOI: 10.1111/add.70174 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Addiction, 2025. Verfasst von Rebekka Syrjanen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Forensic Medicine, Monash University, Southbank, Victoria, Australia. Hauptthemen laut MEDLINE: Alprazolam, Counterfeit Drugs, Seizures, Benzodiazepines. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Health, Victorian State Government, National Health and Medical Research Council, Department of Health, State Government of Victoria.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and aim There is growing evidence of counterfeit benzodiazepine products containing other substances, including non‐regulated benzodiazepine‐type new psychoactive substances (NPSs). This study sought to compare detections of seized suspect counterfeit alprazolam products with clinical cases that reported use of an alprazolam‐containing product to better characterise community use. Design and setting Observational study set in Victoria, Australia, using data from the Victoria Police Drug Sciences Group (which compiles information about seized drugs submitted for evidential analysis and intelligence purposes) and the Emerging Drugs Network of Australia – Victoria (EDNAV) project (a prospective, observational study collecting clinical and analytical data for illicit drug‐related presentations across a network of hospitals in Victoria, Australia). Cases Police seizures expected to contain alprazolam (March 2020 and August 2022) and EDNAV cases with a reported exposure to an alprazolam‐containing product (September 2020 and August 2022).

Measurements

Descriptive study outlining drug detections in seized tablets and blood samples from EDNAV cases, comparing patterns of detection and changes over time.

Findings

A total of 623 police seizures were analysed, most commonly products labelled as ‘Xanax®’ ( n = 266), ‘Kalma®’ ( n = 196) or ‘Mylan®’ ( n = 124). Thirty percent of seizures contained alprazolam only. A benzodiazepine‐type NPS was detected in 375 seizures (60.2%). Exposure to non‐prescribed alprazolam was reported in 11.2% ( n = 125/1112) of EDNAV cases, with 68.8% identifying as male and a median age of 26 years (range 16–68 years). Eighty‐seven cases reported the use of ‘Xanax®’. Alprazolam was detected in 19 EDNAV cases. A benzodiazepine‐type NPS was detected in 78.4% of EDNAV cases. Both datasets saw a shift in detections from etizolam (2020) to clonazolam (2021) and then clobromazolam (2022).

Conclusions

Suspect counterfeit alprazolam products seized by police in Victoria, Australia, in 2020 and 2022 commonly contained other drugs and/or new psychoactive substances, with an apparent limited consumer awareness of the tablet composition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AlprazolamCounterfeit DrugsSeizuresBenzodiazepinesHumansVictoriaProspective StudiesMaleFemaleAdultTabletsMiddle AgedYoung AdultPoliceAdolescent

Stichwörter der Autor:innen

NPSXanax®alprazolambenzodiazepine‐typecounterfeit alprazolamnew psychoactive substancestoxicosurveillance

Substanzen

AlprazolamCounterfeit DrugsTabletsBenzodiazepines

Autor:innen und Institutionen

  • Department of Forensic Medicine, Monash University, Southbank, Victoria, Australia.
  • Victorian Poisons Information Centre, Austin Health, Austin Hospital, Heidelberg, Victoria, Australia.
  • Emergency Department, Austin Health, Austin Hospital, Heidelberg, Victoria, Australia.
  • Department of Critical Care, Melbourne Medical School, The University of Melbourne, Parkville, Victoria, Australia.
  • Emergency Department, Bendigo Health, Bendigo Hospital, Bendigo, Victoria, Australia.
  • Toxicology Department, Victorian Institute of Forensic Medicine, Southbank, Victoria, Australia.

ORCID-Profile: Rebekka Syrjanen, Shaun L Greene, Sarah E Hodgson, Rachelle Abouchedid, Dimitri Gerostamoulos, Jennifer L Schumann

Förderung

  • Department of Health, Victorian State Government
  • National Health and Medical Research Council
  • Department of Health, State Government of Victoria

Zitieren

APA

Syrjanen, R., Greene, S. L., Hodgson, S. E., Abouchedid, R., Gerostamoulos, D., Magee, C., Bremner, M., Schumann, J. L., & Emerging Drugs Network of Australia – Victoria (EDNAV) research group (2025). Counterfeit ‘Xanax®’ tablets: A comparative study of clinical and seizure data in Victoria, Australia. Addiction. https://doi.org/10.1111/add.70174

Vancouver

Syrjanen R, Greene SL, Hodgson SE, Abouchedid R, Gerostamoulos D, Magee C, et al. Counterfeit ‘Xanax®’ tablets: A comparative study of clinical and seizure data in Victoria, Australia. Addiction. 2025. doi:10.1111/add.70174

BibTeX
@article{Syrjanen2025,
  author = {Syrjanen, Rebekka and Greene, Shaun L and Hodgson, Sarah E and Abouchedid, Rachelle and Gerostamoulos, Dimitri and Magee, Christie and Bremner, Melissa and Schumann, Jennifer L and Emerging Drugs Network of Australia – Victoria (EDNAV) research group, Emerging Drugs Network of Australia – Victoria (EDNAV) research group},
  title = {Counterfeit ‘Xanax®’ tablets: A comparative study of clinical and seizure data in Victoria, Australia},
  journal = {Addiction},
  year = {2025},
  doi = {10.1111/add.70174}
}
Kostenlos starten →